NASDAQ:SYNHSyneos Health Stock Price, Forecast & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SYNH stock has increased by 9.1% and is now trading at $62.51.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Syneos Health.

Syneos Health Inc (NASDAQ:SYNH) posted its quarterly earnings results on Thursday, August, 6th. The company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.20. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Syneos Health had a net margin of 4.10% and a return on equity of 9.63%. The company's quarterly revenue was down 13.1% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share.
View Syneos Health's earnings history.

Syneos Health updated its FY20 earnings guidance on Thursday, August, 6th. The company provided EPS guidance of $3.16-3.38 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.00. The company issued revenue guidance of $4.47-4.57 billion, compared to the consensus revenue estimate of $4.45 billion.

12 brokerages have issued 1 year price targets for Syneos Health's shares. Their forecasts range from $45.00 to $82.00. On average, they anticipate Syneos Health's stock price to reach $65.33 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Syneos Health.

News stories about SYNH stock have trended very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a news impact score of -3.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Icon (ICLR), Netflix (NFLX), Square (SQ), AT&T (T), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA) and JD.Com (JD).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.34%), GW&K Investment Management LLC (1.34%), Goldman Sachs Group Inc. (0.81%), Principal Financial Group Inc. (0.70%), Thrivent Financial for Lutherans (0.69%) and Palisade Capital Management LLC NJ (0.58%). Company insiders that own Syneos Health stock include Alistair Macdonald, Jason M Meggs, John M Dineen, Jonathan Olefson, Michelle Keefe, Paul Colvin and Robert Parks.
View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Victory Capital Management Inc., Prudential Financial Inc., Thrivent Financial for Lutherans, Barclays PLC, Mutual of America Capital Management LLC, Bank of New York Mellon Corp, and American International Group Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, Michelle Keefe, and Robert Parks.
View insider buying and selling activity for Syneos Health.

SYNH stock was acquired by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Premier Asset Management LLC, Principal Financial Group Inc., UBS Group AG, Natixis Advisors L.P., State Board of Administration of Florida Retirement System, Envestnet Asset Management Inc., and Scotia Capital Inc.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, Jonathan Olefson, and Paul Colvin.
View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $62.51.

Syneos Health has a market capitalization of $6.52 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

The official website for Syneos Health is www.syneoshealth.com.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]